Asco 2025 · Posters · Cáncer de Mama · Antonio Llombart-Cussac, MD, PhD Volver

ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (ELA) + everolimus (EVE) versus ELA + placebo (PBO) in ER+/HER2- advanced breast cancer (aBC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.

Abstract: TPS1129
Poster Bd #: 103b
Descargar Poster

Antonio Llombart-Cussac, MD, PhD

Medica Scientia Innovation Research (MEDSIR), Hospital Arnau de Vilanova, FISABIO, Translational Oncology Group, Universidad Cardenal Herrera-CEU

Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo